Document is current

Article History

Accepted: 27 June 2024

First Online: 8 July 2024

Compliance with Ethical Standards

:

: KI reports no financial disclosures. GD has received research funding from Amgen and from the American Brain Foundation/American Academy of Neurology. PZ has received an honorarium from Lundbeck Biopharmaceuticals, Board Vitals, and Fieve Clinical Research, collaborates with Headache Science Incorporated without receiving financial support, and has ownership interest in Cymbeline LLC. TT is a consultant/advisor and/or serves on an advisory board for Eli Lilly, Otsuka, Amgen, Pfizer, and Teijin and has received speaker honoraria from Daiichi Sankyo, Otsuka, Eli Lilly, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and grant/funding from Eli Lilly, Pfizer and Tsumura outside the submitted work. Within the prior 36 months TJS has received compensation for consulting with AbbVie, Allergan, Amgen, Axsome, Biodelivery Science, Biohaven, Click Therapeutics, Collegium, Eli Lilly, Ipsen, Linpharma, Lundbeck, Novartis, Satsuma, Scilex, Theranica, and Tonix. He has received royalties from Up To Date and has stock options in Aural Analytics and Nocira. Research funding has been received from American Heart Association, Amgen, Henry Jackson Foundation, National Headache Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Pfizer, Spark Neuro, and United States Department of Defense. CC has served as a consultant for Satsuma and eNeura. She receives research support from the American Heart Association with funds paid to her institution.

: This article does not contain any studies with human or animal subjects performed by any of the authors.